Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

MORPHOSYS : AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 07:35am CEST

MorphoSys AG / AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.

"We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and Slonomics® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

[email protected]:
mailto:[email protected]

 

Press Release:
http://hugin.info/130295/R/1533054/466934.pdf

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1533054
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
06/21MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/20MORPHOSYS : Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Mult..
AQ
06/19MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/15MORPHOSYS : Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic..
PU
06/15MORPHOSYS : Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Mult..
PU
06/15MORPHOSYS : Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Mult..
EQ
06/15MORPHOSYS : Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic..
EQ
06/14ROCHE : New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in ..
AQ
06/13MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/12MORPHOSYS : New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab..
PU
More news
News from SeekingAlpha
06/20MorphoSys (MOR) Presents At The JMP Securities Life Science Conference - Slid.. 
05/31ALEXION PHARMACEUTICALS : Clinical Progress, Acquisitions And The Competition (P.. 
05/03MorphoSys AG's (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call T.. 
05/03MorphoSys AG 2018 Q1 - Results - Earnings Call Slides 
05/03MorphoSys AG reports Q1 results 
Financials (€)
Sales 2018 28,1 M
EBIT 2018 -111 M
Net income 2018 -113 M
Finance 2018 331 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 107x
EV / Sales 2019 53,0x
Capitalization 3 337 M
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 90,1 €
Spread / Average Target -14%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG36.98%3 888
CELLTRION, INC.--.--%33 349
IQVIA HOLDINGS INC6.07%21 424
LONZA GROUP3.53%20 530
INCYTE CORPORATION-22.94%15 692
SEATTLE GENETICS, INC.24.95%10 577